The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Identification of novel biomarkers for Parkinson's disease by metabolomic technologies
Abstract
OBJECTIVE: The pathogenesis of Parkinson's disease (PD) involves complex interactions between environmental and genetic factors. Metabolomics can shed light on alterations in metabolic pathways in many diseases, including neurodegenerative diseases. In the present study, we attempted to elucidate the candidate metabolic pathway(s) associated with PD. METHODS: Serum samples were collected from 35 individuals with idiopathic PD without dementia and 15 healthy age-matched control participants without PD. This analysis used a combination of three independent platforms: ultrahigh-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) optimised for basic species, UPLC/MS/MS optimised for acidic species and gas chromatography/MS (GC/MS). RESULTS: The metabolomic profiles of PD were clearly different from normal controls. PD profiles had significantly lower levels of tryptophan, caffeine and its metabolites, bilirubin and ergothioneine, and significantly higher levels of levodopa metabolites and biliverdin than those of normal controls. Alterations in the bilirubin/biliverdin ratio and ergothioneine can indicate oxidative stress intensity and may suggest elevated oxidative stress and/or insufficient ability for scavenging free radicals, which could contribute to PD pathogenesis. Decreased serum tryptophan level is associated with psychiatric problems in PD. A decrease in serum caffeine levels is consistent with an inverse association of caffeine consumption with development of PD based on past epidemiological studies. CONCLUSIONS: Metabolomic analysis detected biomarkers associated with PD pathogenesis and disease progression. Since critical metabolic biomarkers need to be identified in PD, future studies should include assay validation and replication in independent cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M., & Milgram, E. (2009) · Analytical Chemistry · doi:10.1021/ac901536h · Cited by 1,333
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Etiology and pathogenesis of Parkinson's disease
Schapira, A. H., & Jenner, P. (2011) · Movement Disorders · doi:10.1002/mds.23732 · Cited by 657
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
Tryptophan metabolism, from nutrition to potential therapeutic applications
Le Floc’h, N., Otten, W., & Merlot, E. (2011) · Amino Acids · doi:10.1007/s00726-010-0752-7 · Cited by 561
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El-Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 527
Influence of polyamines on membrane functions
Schuber, F. (1989) · Biochemical Journal · doi:10.1042/bj2600001 · Cited by 430
Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425
Cited by
Applications of multi‐omics analysis in human diseases
Chen, C., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Yang, X., Yang, M., & Liu, G. (2023) · MedComm · doi:10.1002/mco2.315 · Cited by 545
Histidine in Health and Disease: Metabolism, Physiological Importance, and Use as a Supplement
Holeček, M. (2020) · Nutrients · doi:10.3390/nu12030848 · Cited by 485
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
Okuzumi, A., Hatano, T., Matsumoto, G., Nojiri, S., Ueno, S.-I., Imamichi-Tatano, Y., Kimura, H., Kakuta, S., Kondo, A., Fukuhara, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02358-9 · Cited by 313
Self-citationErgothioneine – a diet‐derived antioxidant with therapeutic potential
Halliwell, B., Cheah, I. K., & Tang, R. M. Y. (2018) · FEBS Letters · doi:10.1002/1873-3468.13123 · Cited by 305
The biology of ergothioneine, an antioxidant nutraceutical
Borodina, I., Kenny, L. C., McCarthy, C. M., Paramasivan, K., Pretorius, E., Roberts, T. J., van der Hoek, S. A., & Kell, D. B. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422419000301 · Cited by 296
“are also markedly different in Parkinson’s disease(515), reviewed in Hang et al.”
Background
Metadata
- Authors
- Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P., & Hattori, N.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2015-03-20
- Volume
- 87
- Issue
- 3
- Pages
- 295-301
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2023122194
- Cited by
- 282
- References
- 38
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. https://app.cochat.ai/papers/10.1136/jnnp-2014-309676
- The paper
- Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P., & Hattori, N. (2016). Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2014-309676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.